Drug intelligence / Profile preview

HLK-R042

Development stage: Preclinical
Lead developer: Shenzhen Yaoxin Biotechnology
Modality: Small Molecules
Administration: Topical

Overview

HLK-R042 is a preclinical-stage topical small molecule candidate being developed by Shenzhen Yaoxin Biotechnology (also known as Pharmacin) for the treatment of alopecia areata. The drug is developed using the company's proprietary "Ring-Lock" technology, which is designed to optimize the pharmacokinetic and pharmacodynamic profiles of small molecule inhibitors. HLK-R042 is intended for local application to the scalp to inhibit the Janus kinase (JAK) signaling pathway, thereby reducing the autoimmune-mediated inflammation that leads to hair follicle destruction. As of late 2024, the program remains in the preclinical phase of development.

Other names: HLK-R042HLK-R-042HLK-R 042

Targets

JAK (Janus kinase family)

Beyond the preview

Go deeper on HLK-R042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLK-R042.

Explore the full profile